Investor Relations

OPKO Health Announces Leadership Changes at BioReference Laboratories more »

OPKO'S GeneDx Announces Research Collaboration with Radboud University Medical Center more »

OPKO Health Enrolls First Patient in Phase 2B Study of OPK88004 to Treat Benign Prostatic Hypertrophy more »

OPKO Health Reports 2017 Third Quarter Highlights and Financial Results more »

Code of Business Conduct and Ethics

The Board has adopted a Code of Business Conduct and Ethics that applies to all of our directors, officers (including our Chief Executive Officer, our Chief Financial Officer and our principal accounting officer) and employees.

Notice of Amendment:
On June 14, 2012, the Company’s Board of Directors amended its Code of Business Conduct and Ethics to, among other things, further define various transactions which would constitute a conflict of interest, include provisions prohibiting usurpation of corporate opportunities, impose requirements of fair dealing and confidentiality, and clarify various reporting procedures and obligations for responding to government investigations and media or public inquires.

  Click here for Code

Email  Sign up for email alerts